Category Archives: Cancer Therapies

Eric Lefkofsky Promotes Data-Centric Cancer Therapy

Eric Lefkofsky is known to the world for being the co-founder as well as CEO of Tempus. But it is also important to know how the idea for this startup came about.

Mr Lefkofsky wants to fine-tune the treatment of cancer by making it data driven. He feels that even though a lot of patient data is available, there is a lack of sources to combine genomic information along with therapeutic data.

He says that having a lot of molecular data is not enough. This is because clinical data is also required. There has to be therapeutic data along with data on outcome response. This has to be combined with the information about the DNA and RNA makeup of patients. This will help clinicians in knowing how they will be responding to treatments.

In fact, such kind of data needs to be available freely to researchers and clinicians, and all other associated people. Eric Lefkofsky is the co-founder of Groupon. He was motivated to start with his venture to form Tempus once his wife was diagnosed with cancer. This was when he realized that oncologists were facing a difficulty in doing their jobs due to lack of data. Basically, they lacked the data on how any given treatment will work for any given specific types of patients.

This is how the idea of Tempus came up. It is a layer of technology on top of the existing electronic medical records as well as pathology systems. This helps to aggregate the given data, prune it as per specifications and then feed this refined version back to its original source. This is done to ensure validation as well as verification. There will be a larger data pool that will combine all the data of the patients. This can be used for finding any common patterns between the treatments and results.

Eric Lefkofsky wants people working in oncology as well as on neurological disorders to use this platform for collecting data and using it for analysis. In fact, he feels that all need to make use of this data in order to treat their patients better.


Clay Siegall: A Driving Force in Innovation of Cancer Treatment

Clay B. Siegall is Chief Executive Officer,President, and chairman of the board at Seattle genetics. His scientific training has focused on cancer therapies and he has played a major role in the cancer research community. Over years of practice he has spread his love and passion for helping patience, which is his main priority. He has made Seattle Genetics a top competitor in the development of antibody drug conjugates (ADCs). In 2011 they received their first FDA approval of and antibody drug conjugate. The name of their first drug is ADCETRIS® or generically brentuximab vedotin. Clay Siegall displays superb leadership as he has drove Seattle Genetics to enter into multiple strategic licenses for ADC technology. Media outlet Xconomy has featured Siegall, according to their website Siegall has secured more than 330 million dollars through capital raising activities. Siegall has formed many relationships with major companies to help develop ADCs. These companies include Genentech, MedImmune, CuraGen, Bayer and Progenics. Much of this wouldn’t have happened if not for Clay Siegall’s earlier experiences. He was with the Bristol-Myers Squibb Pharmaceutical Research Institute where he gained a foundation. Prior to that even he went to George Washington University where he gained his Ph.D. The over achieving man has also received many prestigious rewards. The 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences being one of them. The biggest goal of all are the many lives saved from the anti-body conjugates and the plus that they only attack the right cells and not all cells like chemotherapy does. All of this is being greatly forwarded by Clay Siegall, a professional life saver.